ClinicalTrials.gg
TerminatedNCT05213143Updated Apr 19, 2024

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

A Phase 4 interventional study of Lurasidone in Schizophrenia, sponsored by Sumitomo Pharma (Suzhou) Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd. (formerly part of Sumitomo Pharma Co., Ltd.) · Phase 4, Interventional, and Treatment

Why this study was terminated
Company's business decision

From the registry’s dates

  • Primary completion was Nov 2022, 3 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
37th of 39
13 · median 149
Started
2021
with 1 other
Phase 4
7 of 39
none open now
Registered
38th of 39
by date
Lead sponsor
5 of 39
Sumitomo Pharma (Suzhou) Co., Ltd.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 37th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 4, and was the 38th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

An open-label, single-arm and multi-center study for 16 weeks

Read the detailed description

An open-label, single-arm and multi-center study for 16 weeks, to study the improvement of weight gain in patients with schizophrenia who switched from olanzapine to lurasidone.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject aged ≥ 18 to ≤ 65 years old
  • Meet ICD-10 criteria for a primary diagnosis of schizophrenia, the duration must be at least one year
  • Provide written (subject's legal guardian or impartial witness shall sign informed consent if the subject is unable to sign) and is willing and able to comply with the protocol in the opinion of the investigator.
  • Considered to be an appropriate candidate for switching olanzapine due to safety or tolerability concerns
  • Received Olanzapine monotherapy at a dose of 10 to 20mg/d for at least 8 weeks with a (BMI) ≥25kg/m2, the dose of olanzapine has been stable for at least 4 weeks prior to screening. Weight gain during current olanzapine therapy was verified in the subject history.
  • Subject must meet the clinical stability as following criteria:

    1. CGI-S ≤ 4 (at both Screening and Baseline)
    2. PANSS total score ≤ 70 at Screening and Baseline
    3. No exacerbation of schizophrenia has occurred for at least 8 weeks prior to screening

Exclusion criteria

Exclusion Criteria:

  • Subjects with severe or unstable physical diseases (including but not limited to severe or unstable cardiovascular diseases, cerebrovascular diseases, liver and kidney diseases) determined by the investigators.
  • Currently has severe liver function impairment, or serum (ALT) or aspartate aminotransferase (AST) level ≥3 times the value
  • rate \< 50mL/min
  • Subjects had a history of stomach or intestinal surgery or any other condition that could interfere with absorption, distribution, metabolism, or excretion of medications
  • More than 10% weight loss 3 months prior to the screening period
  • A history of malignant tumors (including benign pituitary tumors)
  • Any chronic organic disease of the central nervous system (excluding schizophrenia), such as CNS related tumors and inflammation, active seizures, vascular disease, Parkinson's disease, Alzheimer's disease, or other forms of dementia, myasthenia gravis, and other degenerative diseases. A history of mental retardation or persistent neurological symptoms caused by severe head injury
  • Subjects need to take any potent inhibitor (e.g., ketoconazole, ritonavir, clarithromycin, ritonavir, voriconazole, Mibefradil) or inducer (e.g. rifampicin, avasimibe, St. John's Wort, phenytoin, carbamazepine), drugs for external use in dermatological patients are excluded
  • Subject has a history of treatment with clozapine for psychosis and/or subject has been treated with clozapine (for any reason) within 4 months of baseline
  • Subjects has used long-term antipsychotic drugs in the following time prior to the enrolment
  • Subjects received electroconvulsive therapy (ECT) within 90 days prior to screening, or were expected to require ECT during the study
  • A history of neuroleptic malignant syndrome
  • Severe tardive dyskinesia, severe dystonia, or any other severe dyskinesia
  • Subjects is at risk of suicide or self-mutilation behaviours or the act of endangering others, or other corresponding characteristic behaviour, or a history of suicide
  • Female subjects were pregnant (positive pregnancy test at screening) or breast-feeding or planning pregnancy for the duration of the study, or the partners of male subjects were planning pregnancy for the duration of the study
  • History of severe allergy or ;
  • Angioedema occurred after previous administration of lurasidone;
  • Patients who had previously participated in a clinical study of lurasidone;
  • The subject is participating in or has participated in other clinical trials, including the use of commercially available drugs or medical devices, within 30 days prior to the signing of the ;
  • Any other conditions judged by the investigators that not suitable to participate in this study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Lurasidone

    Lurasidone was oral administrated with a meal or within 30 min after eating in the evening.

    Drug: Lurasidone

Interventions

  • Lurasidone was oral administrated with a meal or within 30 min after eating in the evening. The maintenance dose of olanzapine from Day 0 to Day 6, than tapered until discontinuation from Day 7 to Day 27. Lurasidone initiated with 40mg/d on Day 0, maintained until Day 13, with a flexible dose (40-80mg/d, qd) from Day 28 to Day 111.

06

What researchers measure

Primary outcomes

  1. Mean weight change

    Changes in body weight at the end of treatment compared to baseline

    Time frame: from baseline to week 16

Secondary outcomes

  1. Change in Positive and Negative Syndrome Scale (PANSS) scores

    Change in PANSS scores at the end of treatment compared to baseline.

    Time frame: from baseline to week 16

  2. Change in the Clinical Global Impressions-Severity (CGI-S) scores

    Change in CGI-S scores at the end of treatment compared to baseline.

    Time frame: from baseline to week 16

  3. Change in 12-Item Short Form Survey (SF-12) scores

    Change in SF-12 scores at the end of treatment compared to baseline

    Time frame: from baseline to week 16

  4. Change in waist circumference

    Change in waist circumference at the end of treatment compared to baseline. Wrap the tape around 0.5 to 1.0 cm above the belly button, and measure the circumference.Obese patients wrap a tape measure around the widest part of their waist.

    Time frame: from baseline to week 16

  5. Change in the serum prolactin (PRL)

    Change in PRL at the end of treatment compared to baseline.

    Time frame: from baseline to week 16

  6. Change in Calgary Depression Scale for Schizophrenia (CDSS) scores

    Change in CDSS scores at the end of treatment compared to baseline.

    Time frame: from baseline to week 16

  7. Change in fasting lipids

    Change in fasting lipids(total cholesterol, triglycerides, high density liptein cholesterol, low density lipoprotein, Non-high density liptein cholesterol) at the end of treatment compared to baseline.

    Time frame: from baseline to week 16

  8. Change in fasting plasma glucose

    Change in fasting plasma glucose at the end of treatment compared to baseline.

    Time frame: from baseline to week 16

  9. Change in hemoglobin A1c (HbA1c)

    Change in HbA1c at the end of treatment compared to baseline.

    Time frame: from baseline to week 16

  10. Change in the Epworth Sleepiness Scale

    Change in the Epworth sleepiness scale at the end of treatment compared to baseline. A score of 10 or greater raises concern.

    Time frame: from baseline to week 16

07

Study locations

1 site
  • Beijing Anding Hospital
    Beijing, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Nov 2022, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2021
First posted
Jan 28, 2022
StartActual
Dec 30, 2021
Primary completionActual
Nov 18, 2022
CompletionActual
Nov 18, 2022
Last update
Apr 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05213143
Responsible party
Sponsor
First posted
Jan 28, 2022
Start date
Dec 30, 2021
Primary completion
Nov 18, 2022
Completion
Nov 18, 2022
Last update
Apr 19, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion